This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
10/1/19
1
Transcatheter Aortic Valve Replacement (TAVR)
Mohammad Bashir, MD, FACSSurgical Director TAVR Program
Associate Professor of Cardiothoracic surgeryUniversity of Iowa Carver College of Medicine
Disclosures
• No Financial Disclosures• I participate in clinical trials with Edwards Lifesciences• I will discuss off label use for FDA approved devices
AS- Etiology
Etiology
Senile Calcific (60%)
Bicuspid (30%)
Rheumatic (10%)
Aortic valve Area
Normal: 3-4 cm2
Severe AS: <1.0 cm2
Aortic Stenosis Is Life Threatening and Progresses Rapidly
§ Survival after onset of symptoms is 50% at 2 years and 20% at 5 years§ Surgical intervention for severe aortic stenosis should be performed
promptly once even minor symptoms occur
Overall 3-year survival in operated and unoperated patients with severe aortic stenosis.
Trials randomizing high risk patients to either TAVI or SAVR followed
US CoreValve Pivotal Trial PARTNER 1A
CoreValve, N=390, STS 7.3% vs. SAVR, N=357, STS 7.5%
SAPIEN, N=348, STS 11.8% vs. SAVR, N=351, STS 11.7%
High Risk: High Risk Patients
• TAVR vs. AVR- no difference in mortality
• TAVR – more strokes, less major bleeding
• TAVR and surgical AVR are both acceptable therapies in these high-risk patients
TAVI Clinical TrialsIntermediate Risk 2016
Randomized trial data comparing TAVI to SAVR in intermediate surgical risk patients recently became available
SURTAVI and SURTAVI CAS PARTNER 2A and PARTNER S3i
10/1/19
4
Intermediate risk:
• The results support the use of TAVR as an alternative to surgery in intermediate risk patients.
• Patients who are candidates for transfemoral access, TAVR may result in additional clinical advantages.
• Long-term durability assessments for TAVR valves are still lacking.
TAVI Clinical TrialsLow Risk 2019
• All components of the primary endpoints and all secondary endpoints directionally favored TAVR• Results are only at one year and all patients will be followed for 10 years for
durability• TAVR is now the preferred procedure for the majority of patients with
symptomatic aortic stenosis• Short and intermediate term Hemodynamic data is very favorable in supra-
annular valves.
• More data is needed for Bicuspid, leaflet thrombosis, and younger patients
Low Risk Evolution of the Edwards Balloon-Expandable Transcatheter Valves
* Sheath compatibility for a 23 mm valve
2002Cribier-Edwards
2006SAPIEN
2009
SAPIEN XT
2013
SAPIEN 3
The University of Iowa Experience(Kafa et al. International Academy of Cardiology 2016)
10/1/19
5
20% Increase in TAVR in 2019 Anticipated
27
NEJM9 Publications
9 YearsPercutaneous Double valve in calcified native annulus(TVT 2016)
• 87-year-old woman was referred for class III heart failure management• Past medical history• Chronic kidney disease stage 3• Pulmonary hypertension• Moderate COPD • Atrial fibrillation s/p pacemaker
Percutaneous Double valve in calcified native annulus(TVT 2016)
Percutaneous Double valve in calcified native annulus(TVT 2016)
• STS for AVR/CABG 9.8%• STS score for MVR/CABG was 19%
• Valve team decision was to perform Trans catheter double valve replacement with percutaneous approach for both valves
10/1/19
6
Percutaneous Double valve in calcified native annulus(TVT 2016)
Percutaneous Double valve in calcified native annulus(TVT 2016)
Percutaneous Double valve in calcified native annulus(TVT 2016)
Percutaneous Double valve in calcified native annulus(TVT 2016)
Percutaneous Double valve in calcified native annulus(TVT 2016)
Percutaneous Double valve in calcified native annulus(TVT 2016)
10/1/19
7
Percutaneous Double valve in calcified native annulus(TVT 2016)